Reference
Institute for Clinical and Economic Review (ICER). ICER Uses Observational Real-World Evidence to Update 2018 Assessment on Therapies for Hereditary Angioedema, Finds Therapies Far Less Cost-Effective Than Earlier Estimates. Internet Document : 26 Aug 2021. Available from: URL: https://icer.org/news-insights/press-releases/icer-uses-observational-real-world-evidence-to-update-2018-assessment-on-therapies-for-hereditary-angioedema-finds-therapies-far-less-cost-effective-than-earlier-estimates/
Rights and permissions
About this article
Cite this article
ICER's observational real-world evidence update finds hereditary angioedema therapies less cost effective. PharmacoEcon Outcomes News 886, 32 (2021). https://doi.org/10.1007/s40274-021-08010-3
Published:
Issue Date:
DOI: https://doi.org/10.1007/s40274-021-08010-3